Literature DB >> 849823

Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

J P Miguet, P Mavier, C J Soussy, D Dhumeaux.   

Abstract

The inducing effect of rifampicin (600 mg per day) on the hepatic microsomal drug-metabolizing system has been studied in 7 patients with normal liver after 6 days of oral administration. Using the plasma disappearance rate of antipyrine (15 mg per kg of body weight) as an index of liver microsomal metabolism, a significant decrease in the half-life of antipyrine has been observed: 11.7 +/- (1 sd) 4.7 hr before treatment as compared to 6.9 +/- 2.3 hr on the 7th day. Concomitantly, the half-life of rifampicin was 5.3 +/- 2.1 and 2.7 +/- 0.8 hr on the 1st and 7th day, respectively. These results demonstrate that rifampicin administration for only 6 days leads to the induction of the microsomal mixed function oxidase system in liver. These data are in agreement with the recent hypothesis that rifampicin may play a role in the hepatotoxicity of isoniazid by enhancing its microsomal transformation to a toxic metabolite.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 849823

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Diagnostic and therapeutic problems in a case of adrenal tuberculosis and acute Addison's disease.

Authors:  F Benini; T Savarin; G E Senna; S Durigato; L Vettore
Journal:  J Endocrinol Invest       Date:  1990 Jul-Aug       Impact factor: 4.256

2.  Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 4.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

5.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

6.  The influence of enzyme induction on polymorphic sparteine oxidation.

Authors:  M Eichelbaum; S Mineshita; E E Ohnhaus; C Zekorn
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

7.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 8.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 9.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 10.  The pregnane X receptor in tuberculosis therapeutics.

Authors:  Amina I Shehu; Guangming Li; Wen Xie; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-12-05       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.